comparemela.com

Latest Breaking News On - European lung cancer congress - Page 2 : comparemela.com

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients If.

Hong kongUnited statesBen atwellZhou yiAtholl tweedieChina limitedEuropean lung cancer congress onAmerican cancer societyNational reimbursement drug listStock exchange of hong kongEuropean lung cancer congressInternational agency for research on cancerWorld health organizationExchange commissionSingle institution studyChina national medical products administration

Lung Cancer Screening Unveils Hidden Health Risks

Screening for lung cancer can identify more than lung malignancies.

Serbia generalDaiwei hanInstitute for diagnostic accuracy in groningenEuropean lung cancer congressEuropean union horizonInstitute for oncologyEuropean society for clinical oncologyJelena spasicEuropean societyClinical oncologyDiagnostic accuracyEuropean union

Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.

United statesUniversity of virginiaComunidad autonoma de catalunaMaria rosario garcia campeloRyand gentzlerEnriqueta felipMerck seronoAntonio passaroDaiichi sankyoZofia piotrowskaEli lillySociety for immunotherapy of cancerJazz pharmaceuticalsUniversity hospitala coruEuropean institute of oncologyJanssen pharmaceuticals

China s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC

China s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

European lung cancer congressChina national medical products administrationNational medical products administrationLung cancer

Hutchmed cancer treatment indication accepted for review in China

Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

European lung cancer congressLung cancerHutchmed china

vimarsana © 2020. All Rights Reserved.